37 reports

‘Treatment-resistant depression (TRD)– Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Treatment-resistant depression, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Treatment-resistant depression (TRD) Disease...

  • Depression
  • Therapy
  • Italy
  • Spain
  • France
  • Germany
  • United States
  • United Kingdom
  • Japan

‘Postpartum Depression (PPD) -Market Insights, Epidemiology and Market Forecast– 2030’ report delivers an in-depth understanding of the Postpartum Depression (PPD), historical and forecasted epidemiology as well as the Postpartum Depression (PPD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and...

  • Depression
  • United States
  • Health Expenditure

‘Treatment-resistant depression (TRD) - Market Insights, Epidemiology, and Market Forecast - 2030’ report delivers an in-depth understanding of the Treatment-resistant depression (TRD), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The...

  • Therapy
  • Depression
  • United States
  • Japan
  • United Kingdom
  • Spain
  • France
  • Germany
  • Italy
  • Health Expenditure
  • Depression Prevalence

‘Major Depressive Disorder (MDD)–Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Major Depressive Disorder (MDD), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Major Depressive Disorder (MDD) Disease Understanding Depression...

  • Depression
  • Spain
  • France
  • Germany
  • United States
  • Italy
  • United Kingdom
  • World

Chart ##: Depression (Billion Yuan)

  • Antidepressant
  • Depression
  • China
  • Industrial Production
  • Labour Force

## Depression

  • Depression
  • Anxiety Disorder
  • Indiana
  • Drug Approval
  • Prescription Drug Sales

‘Major Depressive Disorder—Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Major Depressive Disorder, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain and the United Kingdom), and Japan. The Major Depressive...

  • Depression
  • United States
  • Spain
  • France
  • Germany
  • Italy
  • United Kingdom
  • Japan
  • Health Expenditure
  • Depression Prevalence

Depression Prevalence Hospital Occupancy Rate Depression

  • Depression
  • World
  • Depression Prevalence
  • Disability-Adjusted Life Years

TABLE ## TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT- RESISTANT DEPRESSION, BY REGION, 2018–2025 (USD MILLION)

  • Neurological Disorder
  • Chronic Pain
  • Depression
  • North America
  • APAC
  • Europe
  • Drug Approval
  • Chronic Disease Prevalence

“AXS-05 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Treatment Resistant Depression in 7 Major Markets. A detailed picture of the AXS-05 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the...

  • Depression
  • Research And Development
  • Europe
  • World
  • Spain
  • France
  • Japan
  • Germany
  • Italy
  • United Kingdom
  • United States
  • Health Expenditure

Small Molecules to Antagonize mGlu## for Anxiety and Depression Vanderbilt University NA NA

  • Therapy
  • Psychotic Disorder
  • Drug Development
  • Depression
  • Pharmaceutical
  • Mental Health
  • World
  • Health Provider Density

“Major Depressive Disorder – Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage,...

  • Depression
  • World

This report is 80% complete and can be delivered within three working days post order confirmation and will include the latest impact analysis of Covid-19 in 2020 and forecast. Global Behavioral Rehabilitation Market By Application (Anxiety Disorder, Mood Disorder, Substance Abuse Disorder, Personality Disorder, Attention...

  • Mental Health
  • Specialty Hospital
  • Depression
  • Anxiety Disorder
  • World
  • Depression Prevalence

Chart ##: Depression (Billion Yuan)

  • Antidepressant
  • Depression
  • China
  • Industrial Production
  • Labour Force

“REL-1017 - Emerging Insight and Market Forecast - 2030” the report provides comprehensive insights about an investigational product for Major Depressive Disorder in 7 Major Markets. A detailed picture of the REL-1017 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the...

  • Depression
  • Therapy
  • Research And Development
  • Clinical Trial
  • Europe
  • World
  • Spain
  • France
  • Japan
  • Germany
  • Italy
  • United Kingdom
  • United States
  • Health Expenditure

Small Molecules to Antagonize mGlu## for Anxiety and Depression Vanderbilt University NA NA

  • Therapy
  • Psychotic Disorder
  • Drug Development
  • Depression
  • Mental Health
  • World
  • Health Provider Density
  • Prescription Drug Sales

“Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Acetylcholine Receptor (AChR) Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment...

  • Therapy
  • Depression
  • World

Depression Mental Health

  • Mental Health
  • Therapy
  • Depression
  • Addiction Disorder
  • Clinical Trial
  • World
  • Depression Prevalence
  • Drug Approval

In October 2017, Cadent Therapeutics had announced that it has earned a milestone payment from Novartis for the initiation of a Phase ## clinical study of NMDA receptor negative allosteric modulator (NAM) for the treatment of treatment-resistant depression.

  • Therapy
  • Depression
  • Chronic Pain
  • World
  • Depression Prevalence
  • Prescription Drug Sales

Small Molecules to Antagonize mGlu## for Anxiety and Depression Vanderbilt University NA NA

  • Therapy
  • Psychotic Disorder
  • Drug Development
  • Depression
  • Mental Health
  • World
  • Health Provider Density
  • Prescription Drug Sales

Biopolar Depression

  • Depression
  • United States
  • Mental Health Expenditure
  • Spending On Medicines

May ##: Nexstim sells first NBT system in Germany for depression therapy and research

  • Depression
  • Chronic Pain
  • Canada
  • Medical Devices Sales
  • Direct Sales

Top ## countries with the most depression and anxiety ##

  • Depression
  • Healthcare
  • Beverage
  • Functional Food
  • World
  • Labour Utilisation
  • Health Insurance Claims

Melancholic depression

  • Depression
  • World
  • United States
  • Japan
  • Canada
  • Depression Prevalence
  • Disability-Adjusted Life Years

Drug Overview: Rexulti

8770 10000 7800

Drug Overview  Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; Otsuka/Lundbeck), displaying partial agonism of dopamine receptors in the central nervous...

  • Antipsychotic
  • Neurology
  • Clinical Trial
  • Depression
  • United States

Drug Overview: Vraylar

8770 10000 7800

Drug Overview  Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor. Vraylar is also a partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A receptors. Most atypical antipsychotics...

  • Antipsychotic
  • Depression

Bipolar Disorder (Manic Depression)

  • Bipolar Disorder
  • Depression
  • World
  • Depression Prevalence
  • Diagnostic Imaging Density

Treatment Resistant Depression - Dormant Projects, H## 2016

  • Therapy
  • Depression
  • World
  • Drug Approval
  • Depression Prevalence

Treatment Resistant Depression

  • Therapy
  • Depression
  • Research And Development
  • World
  • Pharmaceutical Registrations
  • Drug Approval

Small Molecules to Antagonize NMDA Receptor ##B for Depression and Major Depressive Disorder – Drug Profile

  • Depression
  • World
  • Depression Prevalence